Novo Nordisk's amylin drug CagriSema is expected to launch early next year, with the standalone cagrilintide and high-dose CagriSema anticipated in 2028. New data released by Novo Nordisk this week showed that CagriSema not only aids in weight loss but also reduces "food noise" (persistent thoughts about food) and improves organ and bone health. It also alters the brain's response to high-calorie foods in regions associated with craving, pleasure, and self-control. Novo Nordisk is also developing amycretin, a drug that simultaneously mimics the effects of GLP-1 and amylin.